Intravesical formalin for hemorrhagic cystitis: A contemporary cohort

Matthew J. Ziegelmann, Stephen A. Boorjian, Daniel D. Joyce, Brian D. Montgomery, Brian J. Linder

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Introduction: Hemorrhagic cystitis presents a difficult clinical challenge, yet data regarding treatment options is sparse. Here, we sought to evaluate outcomes of a contemporary cohort of patients treated with intravesical formalin for hemorrhagic cystitis. Methods: We identified a retrospective cohort of eight patients managed with formalin for hemorrhagic cystitis from 2000-2014. All patients failed prior measures, including bladder irrigation, clot evacuation, and other intravesical agents. Treatment success was defined as hematuria resolution during the given hospitalization without use of additional invasive therapies. We also evaluated treatment complications and additional treatments following hospital dismissal. Results: Etiology of cystitis was radiation for malignancy in all cases. The formalin concentration ranged from 1-4%, with escalation used in treatment failures. Five patients (62.5%) received a single dose of 1% formalin, two patients received two doses, and one patient received three doses. Notably, intraoperative cystography identified vesicoureteral reflux (VUR) in 50.0% of patients. Six patients (75.0%) achieved treatment success, with a median time to resolution of four days (range 1-17 days). Of those refractory to formalin, one was managed with indwelling nephrostomy tubes and one underwent cystectomy. Median followup was eight months. Of the responders, two eventually required cystectomy, one for recurrent hematuria and one for recalcitrant bladder neck contracture and bladder dysfunction. The remaining four patients (50%) required no additional therapy. Conclusions: Formalin remains an important tool for treating refractory hemorrhagic cystitis, with roughly 75.0% of patients requiring no additional therapy prior to hospital discharge. Notably, there is a risk of bladder dysfunction following formalin.

Original languageEnglish (US)
Pages (from-to)E79-E82
JournalJournal of the Canadian Urological Association
Issue number3-4
StatePublished - Mar 2017

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Intravesical formalin for hemorrhagic cystitis: A contemporary cohort'. Together they form a unique fingerprint.

Cite this